A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab
收藏DataCite Commons2026-03-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012917/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study provided efficacy, safety, and pharmacokinetics (PK) data for patients with relapsing multiple sclerosis (RMS) in Japan and the other countries
提供机构：
Vivli
创建时间：
2026-03-27
